Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Non-Current Liabilities (2016 - 2026)

Aytu Biopharma has reported Other Non-Current Liabilities over the past 11 years, most recently at $4.9 million for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 23.25% to $4.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.9 million through Dec 2025, down 23.25% year-over-year, with the annual reading at $4.9 million for FY2025, 8.59% up from the prior year.
  • Other Non-Current Liabilities was $4.9 million for Q4 2025 at Aytu Biopharma, down from $20.4 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $20.4 million in Q3 2025 and troughed at $371000.0 in Q1 2022.
  • The 5-year median for Other Non-Current Liabilities is $6.4 million (2024), against an average of $7.8 million.
  • The largest YoY upside for Other Non-Current Liabilities was 167918.18% in 2021 against a maximum downside of 95.55% in 2021.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $560000.0 in 2021, then soared by 641.96% to $4.2 million in 2022, then soared by 52.68% to $6.3 million in 2023, then grew by 0.66% to $6.4 million in 2024, then fell by 23.25% to $4.9 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Other Non-Current Liabilities are $4.9 million (Q4 2025), $20.4 million (Q3 2025), and $4.9 million (Q2 2025).